Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Constipation, Signs and Symptoms, Digestive
Interventions
DRUG

Naloxegol

Opioid Antagonist

Trial Locations (16)

5000

Odense University Hospital, Odense

5021

Haukeland Universitetssykehus, Bergen

7006

St. Olavs Hospital, Trondheim

28046

Hospital Infantil Universitario Nino Jesus, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

28660

Unidad de Hematología y Oncología Pediátrica - Hospital Universitario HM Monteprincipe, Madrid

31096

Rambam Medical Center, Oncology Institute, Haifa

49202

Schneider Children Medical Center, Petah Tikva

0372

Oslo University Hospital - Rikshospitalet, Oslo

08035

Pediatric Oncology Unit Hospital Vall d'Hebron, Barcelona

03191

Hospital Universitario Virgen de la Arrixaca, Murcia

LS1 3EX

The Leeds Teaching Hosptial NHS Trust, Leeds

L12 2AP

Alder Hey Children's Hospital, Liverpool

SW3 6JJ

Royal Marsden Hospital, London

NG7 2UH

Nottingham Children's Hospital, Nottingham

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors
lead

Kyowa Kirin Pharmaceutical Development Ltd

INDUSTRY